Vanderbilt-wide Limited Submission Opportunity

NCI Cancer Screening Research Network Clinical Research Cooperative Agreements (UG1)

Applications due December 19, 2022

Vanderbilt (VU + VUMC): This is a joint competition for VU and VUMC investigators. All investigators should follow these instructions.

Overview:

Vanderbilt (VU and VUMC, collaboratively) may submit one application per RFA for the National Cancer Institute (NCI) Cancer Screening Research Network (CSRN) Clinical Research Cooperative Agreement (UG1) programs. There are three separate RFAs for Accrual, Enrollment, and Screening Site (ACCESS) Hubs, Statistics and Data Management Center (SDMC) and a Coordinating and Communication Center (CCC): RFA-CA-23-020, RFA-CA-23-021, and RFA-CA-23-022.

Screening for cancer is a process that involves multiple steps and clinical care from primary care or other clinicians. These three funding opportunities will support a comprehensive effort by the NCI to provide infrastructure to develop the CSRN to efficiently conduct cancer screening clinical trials and other important screening-related studies within clinical practice including the recruitment of participants from diverse, frequently underrepresented populations.

The primary goal of the CSRN is the conduct of multi-center cancer screening trials and studies. The CSRN will engage these populations in rigorous studies focused on cancer screening to improve early cancer detection and evaluate emerging cancer screening modalities with the ultimate goal of reducing cancer incidence, and cancer-related morbidity and mortality.

The CSRN will support the following components that will be individually awarded through the respective FOAs indicated below:

- **CSRN ACCESS Hubs** (RFA-CA-23-020) will establish multi-disciplinary teams to recruit participants to CSRN trials and studies, conduct the screening protocols, and participate in the scientific development and implementation of those trials and studies. Requested budget must not exceed $750,000 in direct costs per year.
- **CSRN Statistics and Data Management Center (SDMC)** (RFA-CA-23-021) will provide statistical expertise and centralized data management, quality control, and reporting in support of CSRN clinical trials and other cancer screening studies. Budgets are not limited but need to reflect the actual needs of the proposed project.
- **CSRN Coordinating and Communication Center (CCC)** (RFA-CA-23-022) will provide cancer screening expertise and clinical trial leadership and is responsible for the coordination of all aspects of study operations, as well as the development and
implementation of communication activities. Budgets are not limited but need to reflect the actual needs of the proposed project.

See solicitations for full program and eligibility details:

- **RFA-CA-23-020** – ACCESS Hubs UG1 Clinical Trial Required
- **RFA-CA-23-021** – SDMC UG1 Clinical Trial Required
- **RFA-CA-23-022** – CCC UG1 Clinical Trial Required

**Note:** NCI will not review applications that propose evaluating technology for the purpose of detecting the recurrence of previously treated cancers and applications that do not address NCI’s scientific mission.

**Internal Application Process:**

Anyone interested in being considered to submit a proposal must submit the following materials to [LSO@vanderbilt.edu](mailto:LSO@vanderbilt.edu) by **5 p.m. on December 19**. Please indicate which RFA you are applying for in your email.

1. 1-page LOI including brief project overview, list of collaborators, and expected budget request;
2. Statement of support from department chair/center director;
3. NIH Biosketch or up to 5-page CV

Those chosen to submit a proposal will submit a Letter of Intent by January 28, 2023 and full proposal by February 28, 2023.

Any questions about this opportunity or the LSO process may be directed to [LSO@vanderbilt.edu](mailto:LSO@vanderbilt.edu).